| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SUSMED,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥537.00 |
| 52 Week High | JP¥1,744.00 |
| 52 Week Low | JP¥375.00 |
| Beta | 1.59 |
| 11 Month Change | -2.54% |
| 3 Month Change | 0% |
| 1 Year Change | -66.69% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4263 | JP Healthcare Services | JP Market | |
|---|---|---|---|
| 7D | 10.5% | 12.1% | 1.1% |
| 1Y | -66.7% | -39.2% | 14.0% |
Return vs Industry: 4263 underperformed the JP Healthcare Services industry which returned -39.2% over the past year.
Return vs Market: 4263 underperformed the JP Market which returned 16.4% over the past year.
Price Volatility
| 4263 volatility | |
|---|---|
| 4263 Average Weekly Movement | 8.9% |
| Healthcare Services Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in JP Market | 10.1% |
| 10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4263's share price has been volatile over the past 3 months.
Volatility Over Time: 4263's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Taro Ueno | www.susmed.co.jp |
SUSMED,Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease.
SUSMED,Inc. Fundamentals Summary
| 4263 fundamental statistics | |
|---|---|
| Market cap | JP¥9.00b |
| Earnings (TTM) | -JP¥357.00m |
| Revenue (TTM) | JP¥340.00m |
26.5x
P/S Ratio-25.2x
P/E RatioIs 4263 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4263 income statement (TTM) | |
|---|---|
| Revenue | JP¥340.00m |
| Cost of Revenue | JP¥13.00m |
| Gross Profit | JP¥327.00m |
| Other Expenses | JP¥684.00m |
| Earnings | -JP¥357.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -21.30 |
| Gross Margin | 96.18% |
| Net Profit Margin | -105.00% |
| Debt/Equity Ratio | 0% |
How did 4263 perform over the long term?
See historical performance and comparison